JP2017173313A - Component analyzer - Google Patents

Abstract

PROBLEM TO BE SOLVED: To propose a component analyzer with which it is possible to improve the reliability of an analysis result.SOLUTION: A component analyzer 6 comprises a spectrum acquisition unit 71 and a component identification unit 73. The spectrum acquisition unit 71 acquires a Raman spectrum that indicates intensity distribution for each wavelength in Raman scattered light. The component identification unit 73 searches for and identifies multiple kinds of sugar component included in blood or interstitial fluid on the basis of the Raman spectrum acquired by the spectrum acquisition unit 71. The multiple kinds of sugar component include, for example, a monosaccharide, a disaccharide, and a trisaccharide. The component identification unit 73 may be constituted to search for multiple kinds of sugar component included in blood or interstitial fluid, and search for and identify an urea component, a medicine component, or an ascorbic acid component.SELECTED DRAWING: Figure 2

Description

  The present invention relates to a component analyzer and is suitable for analyzing components in blood.

  Concerning component analysis in blood, for example, the cornea of the eyeball is irradiated with a monochromatic or single-wavelength excitation light beam from the visible light to the near infrared region, and based on the Raman scattering spectrum obtained from the cornea. An analyzer for analyzing intraocular blood glucose has been proposed (see Patent Document 1 below).

According to Patent Document 1, the shift wave number from the excitation wavelength is 420-1500 cm ⁻¹ or 2850-3000 cm ⁻¹ , preferably 420-450 cm ⁻¹ , 460-550 cm ⁻¹ , 750-800 cm ⁻¹ , 850- ^{940cm -1, 1000~1090cm -1, 1090~1170cm -1} , 1200~1300cm -1, 1300~1390cm -1, glucose quantitated using a Raman scattering peak at 1400～1500Cm ^-1 or 2850～3000Cm ^-1 It is described as possible.

The excitation 550～1500Cm ^-1 or 2900～3050Cm ^-1 in a shift wavenumber from the wavelength, preferably ^{550~620cm -1, 650~700cm -1, 780~870cm -1} , 900~980cm -1, 1000~ It is described that fructose, which is a saccharide other than glucose, can be quantified using Raman scattering peaks at 1150 cm ⁻¹ , 1200 to 1300 cm ⁻¹ , 1400 to 1480 cm ⁻¹ or 2900 to 3050 cm ⁻¹ .

JP-A-9-1222075

  However, in the analyzer of the above-mentioned Patent Document 1, there is a portion where the numerical value is overlapped between the Raman scattering peak used for quantification of glucose and the Raman scattering peak used for quantification of fructose. For this reason, in the analyzer of the above-mentioned patent document 1, it is doubtful whether the quantified blood component indicates a component that should be truly quantified, and it is considered that the reliability of the analysis result is lacking.

  Therefore, the present invention proposes a component analyzer that can improve the reliability of analysis results.

  The component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and is included in blood or interstitial fluid based on the Raman spectrum acquired by the spectrum acquisition unit. And a component identification unit that searches and identifies a plurality of types of sugar components.

  According to such a component analyzer, it becomes possible to subdivide and quantify sugar components contained in blood or interstitial fluid, which is one of the important indicators in the discovery and treatment of diseases such as diabetes. More detailed information can be given compared to the case of capturing the sugar component of the whole.

  In addition, it is preferable that the said component identification part searches and identifies the sugar component of a monosaccharide, a disaccharide, and a trisaccharide.

  In such a case, it is possible to subdivide the types that approximate the structure of the saccharide and quantify it more locally, and to give more detailed information accordingly.

  Moreover, it is preferable that the said component identification part searches and identifies the urea component contained in the said blood or the said interstitial fluid while searching the multiple types of sugar component contained in the said blood or the said interstitial fluid.

  In this case, it is possible to provide an important index for the prevention, early detection and treatment of renal diseases that are likely to be associated with diabetes simultaneously with the prevention, early detection and treatment of diabetes.

  Moreover, it is preferable that the said component identification part searches and identifies the chemical | medical agent component contained in the said blood or the said interstitial fluid while searching the multiple types of sugar component contained in the said blood or the said interstitial fluid.

  When it does in this way, it becomes possible to quantify the chemical | medical agent component which has a possibility of affecting the saccharide | sugar component in blood or interstitial fluid with a saccharide | sugar component. Therefore, when the sugar component contained in blood or interstitial fluid is not within the normal range, it is possible to provide an index for determining whether the factor is a drug component.

  Moreover, it is preferable that the said component identification part searches and identifies the ascorbic acid component contained in the said blood or the said interstitial fluid while searching for the multiple types of sugar component contained in the said blood or the said interstitial fluid.

  When it does in this way, the presence or absence of ascorbic acid deficiency resulting from diabetes can be given as information. Therefore, it is possible to give a more detailed index that is important for the prevention, early detection, and treatment of diabetes.

  In addition, when a peak corresponding to a component contained in the blood or the interstitial fluid is detected from the Raman spectrum acquired by the spectrum acquisition unit, a quantification unit that further obtains a concentration based on the intensity of the peak is further provided. It's also good.

  In addition, it is preferable to further include a notification unit that notifies that there is a drug component in the blood or the interstitial fluid when the concentration of the drug component contained in the blood or the interstitial fluid is equal to or higher than a specified value.

  When it does in this way, when the density | concentration of the saccharide | sugar component contained in the blood or interstitial fluid is not in a normal range, the opportunity which judges whether the factor is a chemical | medical agent component can be given.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Alternatively, 904 cm ⁻¹ is set as the center wave number of the peak appearing in the Raman spectrum when the interstitial fluid contains a glucose component.

When the glucose component is contained in blood or interstitial fluid, it has been experimentally confirmed that a peak appears accurately at 904 cm ⁻¹ of the Raman spectrum and has reproducibility. Therefore, the glucose component in blood or interstitial fluid can be pinpointed and accurately quantified.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Alternatively, when the interstitial fluid contains a fructose component, 620 cm ⁻¹ and 2940 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum.

If the fructose component is contained in the blood or interstitial fluid, the exact peak at 620 cm ^-1 and 2940 cm ^-1 of the Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, the fructose component in blood or interstitial fluid can be pinpointed and accurately quantified.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Alternatively, 546 cm ⁻¹ and 2898 cm ⁻¹ are set as center wave numbers of peaks appearing in the Raman spectrum when the interstitial fluid contains a maltose component.

If the maltose component is contained in the blood or interstitial fluid, the exact peak at 546cm ^-1 and 2898cm ^-1 of Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, maltose components in blood or interstitial fluid can be pinpointed and accurately quantified.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Alternatively, when the interstitial fluid contains a maltotriose component, 470 cm ⁻¹ and 922 cm ⁻¹ are set as center wave numbers of peaks appearing in the Raman spectrum.

If maltotriose component is contained in the blood or interstitial fluid, the exact peak at 470 cm ^-1 and 922cm ^-1 in a Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, the maltotriose component in the blood or interstitial fluid can be pinpointed and accurately quantified.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Alternatively, 1002 cm ⁻¹ is set as the center wave number of a peak appearing in the Raman spectrum when the interstitial fluid contains a urea component.

When a urea component is contained in blood or interstitial fluid, it has been experimentally confirmed that it accurately appears at 1002 cm ⁻¹ of the Raman spectrum and has reproducibility. Therefore, the urea component in blood or interstitial fluid can be pinpointed and accurately quantified.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Alternatively, when the interstitial fluid contains an acetylsalicylic acid component, 804 cm ⁻¹ , 1032 cm ⁻¹ , 1152 cm ⁻¹ and 1198 cm ⁻¹ are set as the center wave numbers of the peaks appearing in the Raman spectrum. And

If acetylsalicylic acid component is contained in the blood or interstitial fluid ^check, 804cm -1 in a Raman ^{spectrum, 1032cm -1,} at 1152cm ^-1 and 1198cm ^-1 by exactly appearing there is experiment that reproducible Has been. Therefore, the acetylsalicylic acid component in blood or interstitial fluid can be pinpointed and accurately quantified.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Alternatively, when the interstitial fluid contains an acetaminophen component, 854 cm ⁻¹ and 1324 cm ⁻¹ are set as center wave numbers of peaks appearing in the Raman spectrum.

If acetaminophen component is contained in the blood or interstitial fluid, it appeared exactly at 854cm ^-1 and 1324cm ^-1 of Raman spectrum there is also the reproducibility has been confirmed by experiments. Therefore, the acetaminophen component in blood or interstitial fluid can be pinpointed and accurately quantified.

In addition, the component analyzer of the present invention includes a spectrum acquisition unit that acquires a Raman spectrum indicating an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum according to a component contained in blood or interstitial fluid. A component identification unit that searches and identifies a component contained in the blood or the interstitial fluid based on a wave number set as a central wave number and a Raman spectrum acquired by the spectrum acquisition unit; Or, ascorbic acid is contained in the interstitial fluid, 820 cm ⁻¹ and 1682 cm ⁻¹ are set as center wave numbers of peaks appearing in the Raman spectrum.

If ascorbic acid component is contained in the blood or interstitial fluid, it appeared exactly at 820 cm ^-1 and 1682 cm ^-1 in the Raman spectrum there is also the reproducibility has been confirmed by experiments. Therefore, the ascorbic acid component in blood or interstitial fluid can be pinpointed and accurately quantified.

  As described above, according to the present invention, a component analyzer that can improve the reliability of analysis results is provided.

It is a figure which shows the structure of a component analysis system. It is a figure which shows the structure of the component analyzer in 1st Embodiment. It is a graph which illustrates the calibration curve of glucose. It is a graph which illustrates the calibration curve of fructose. It is a graph which illustrates the calibration curve of maltose. It is a graph which illustrates a calibration curve of maltotriose. It is a flowchart which shows the 1st component analysis method. It is a figure which shows the structure of the component analyzer in 2nd Embodiment. It is a flowchart which shows the 2nd component analysis method. It is a figure which shows the structure of another component analysis system. It is a figure which shows the Raman spectrum of the aqueous solution sample containing the glucose component of a known density | concentration. Is a diagram showing a Raman spectrum of an aqueous solution sample containing fructose component of known concentration ^{(200cm -1 ~1000cm} -1). Is a diagram showing a Raman spectrum of an aqueous solution sample containing fructose component of known concentration ^{(2700cm -1 ~3100cm} -1). It is a diagram showing a Raman spectrum of an aqueous solution sample containing maltose component of known concentration ^{(200cm -1 ~1000cm} -1). It is a diagram showing a Raman spectrum of an aqueous solution sample containing maltose component of known concentration ^{(2700cm -1 ~3100cm} -1). Shows the Raman spectrum of an aqueous solution sample containing maltotriose component of known concentration ^{(200cm -1 ~1000cm} -1). It is a diagram showing a Raman spectrum of an aqueous solution sample containing maltotriose component of known concentration ^{(800cm -1 ~1000cm} -1). It is a figure which shows the Raman spectrum of the aqueous solution sample containing the urea component of a known density | concentration. It is a diagram showing a Raman spectrum of an aqueous solution sample containing acetylsalicylic acid component of known concentration ^{(200cm -1 ~1000cm} -1). It is a diagram showing a Raman spectrum of an aqueous solution sample containing acetylsalicylic acid component of known concentration ^{(1000cm -1 ~1500cm} -1). Is a diagram showing a Raman spectrum of the aqueous solution samples containing acetaminophen component of known concentration ^{(200cm -1 ~1000cm} -1). Is a diagram showing a Raman spectrum of the aqueous solution samples containing acetaminophen component of known concentration ^{(1000cm -1 ~3000cm} -1). Is a diagram showing a Raman spectrum of an aqueous solution sample containing ascorbic acid component of known concentration ^{(800cm -1 ~1000cm} -1). Is a diagram showing a Raman spectrum of an aqueous solution sample containing ascorbic acid component of known concentration ^{(1000cm -1 ~3000cm} -1).

  Hereinafter, an embodiment for implementing a component analyzer according to the present invention and its modification will be exemplified with reference to the accompanying drawings. The following embodiments and modifications thereof are intended to facilitate understanding of the present invention and are not intended to limit the present invention. The present invention can be changed and improved without departing from the spirit of the present invention.

(1) Embodiment <Configuration of Component Analysis System>
FIG. 1 is a diagram showing a configuration of a component analysis system. As shown in FIG. 1, the component analysis system 1 of the first embodiment is a system that analyzes and analyzes the spectrum of Raman scattered light generated in a sample SPL by irradiation of excitation light, and includes a light source 2, a reflector 3, and an optical system. 4. The spectroscope 5 and the component analyzer 6 are provided as main components. In the present embodiment, blood collected from a person is used as the sample SPL.

  The light source 2 emits excitation light to be irradiated on the sample SPL. The shorter the excitation wavelength of the excitation light, the higher the efficiency of Raman scattering and the higher the spatial resolution. Therefore, a solid laser is preferable as the light source 2. The spectrum of Raman scattered light indicates the difference (Raman shift amount) of the wave number of Raman scattered light with respect to the wave number of pump light, and therefore the pump wavelength is preferably a single wavelength. As a specific example of the excitation wavelength, for example, a single wavelength selected from 514 nm, 532 nm, 633 nm, 670 nm, and 785 nm is used.

  The reflector 3 reflects the light emitted from the light source 2 and guides it to the sample SPL. In addition, as long as the light emitted from the light source 2 is guided to the sample SPL, another member may be employed instead of the reflector 3 or in addition to the reflector 3.

  The optical system 4 guides Raman scattered light generated in the sample SPL to the spectrometer 5. When the sample SPL is irradiated with excitation light, the interaction between the excitation light and the sample SPL generates Raman scattered light having a wavelength different from that of the excitation light in the sample SPL, and a Rayleigh having the same wavelength as the excitation light. Scattered light is generated. The optical system 4 of this embodiment has a filter 41 for removing the Rayleigh scattered light on the waveguide, and guides the Raman scattered light obtained through the filter 41 to the spectrometer 5. .

  The spectroscope 5 includes a diffraction grating 51 and a photodetector 52. The diffraction grating 51 divides the light supplied from the sample SPL via the optical system 4 for each wavelength and guides it to the light receiving surface of the photodetector 52. The photodetector 52 has a plurality of light receiving elements arranged in one dimension or two dimensions in the light receiving surface. The photodetector 52 stores charges proportional to the intensity of Raman scattered light of each wavelength exposed to the light receiving element in the light receiving surface, and stores Raman spectrum data indicating the intensity distribution of each wavelength in the Raman scattered light. Output to the component analyzer 6. Specific examples of the photodetector 52 include a photodiode, a CCD (Charge Coupled Device), a CMOS (Complementary Metal Oxide Semiconductor), and the like.

  The component analyzer 6 searches for the component (blood component) contained in the blood as the sample SPL based on the data given from the photodetector 52 of the spectroscope 5, and obtains the concentration of the blood component detected as the search result. It is like that. In addition, the component analyzer 6 notifies the type and concentration of the blood component that the sample SPL has as necessary.

  As the component analyzer 6, the first embodiment and the second embodiment are illustrated.

(1-1) Component Analyzer in First Embodiment <Configuration of Component Analyzer>
FIG. 2 is a diagram showing an outline of the configuration of the component analyzer in the first embodiment. As shown in FIG. 2, the component analysis apparatus 6 includes an input unit 61, a storage unit 62, a display unit 63, and a control unit 64.

  The input unit 61 is a part that can input various types of information such as commands and setting values according to user operations. Specific examples of the input unit 61 include a mouse, a keyboard, and a portable semiconductor memory connector. Examples of the semiconductor memory include a USB (Universal Serial Bus) memory and a CF (Compact Flash) memory.

  The storage unit 62 is a part that stores data provided from the input unit 61 or the control unit 64 and reads out the stored data. Specific examples of the storage unit 62 include a magnetic disk represented by HD (Hard Disk), a semiconductor memory, or an optical disk.

  The storage unit 62 includes a first storage area for storing various programs, a second storage area for storing various data such as setting data input from the input unit 61, and an expansion for expanding the programs and data. And area. In the first storage area of the present embodiment, a component analysis program for executing processing for analyzing blood components is stored.

  The display unit 63 is a part that displays information indicated by data provided from the control unit 64. Specific examples of the display unit 63 include a liquid crystal display, an EL (Electro Luminescence) display, a plasma display, and the like.

  The control unit 64 controls the component analyzer 6 based on a program stored in the first storage area of the storage unit 62 and data stored in the second storage area of the storage unit 62. .

  When the control unit 64 reads the component analysis program stored in the first storage area of the storage unit 62, the control unit 64 develops the read component analysis program in the development region of the storage unit 62. In this case, the control unit 64 functions as a spectrum acquisition unit 71, a conversion unit 72, a component identification unit 73, a quantification unit 74, and a notification unit 75, and executes component analysis processing for analyzing components contained in blood.

  The spectrum acquisition unit 71 appropriately adjusts the intensity of light to be emitted from the light source 2 to drive the light source 2, and sequentially detects the light detector of the spectroscope 5 through the light source 2, the reflector 3, the sample SPL, and the optical system 4. The data of the Raman spectrum output from 52 is acquired.

  The conversion unit 72 converts the wavelength of the Raman spectrum acquired by the spectrum acquisition unit 71 into a Raman shift amount. Specifically, each wavelength in the Raman spectrum is converted into a wave number that is the number of waves included in the unit length, and each converted wave number is a difference from the wave number of the excitation light emitted from the light source 2. It is converted as a certain amount of Raman shift. As a result, for example, a Raman spectrum having the vertical axis as the intensity and the horizontal axis as the wavelength becomes a Raman spectrum having the vertical axis as the intensity and the horizontal axis as the Raman shift amount. The substance is known to have a specific vibration energy depending on its structure. The amount of Raman shift, which is the difference between the wave number (frequency) of Raman scattered light and the wave number (frequency) of incident light, is It is a unique value that reflects the structure.

  The component identification unit 73 searches and identifies the blood component based on the Raman spectrum converted by the conversion unit 72 and the wave number set as the center wave number of the peak that appears in the Raman spectrum according to the blood component.

In the present embodiment, 904 cm ⁻¹ is set as the center wave number of the peak that appears in the Raman spectrum when the blood contains a glucose component. Further, 620 cm ⁻¹ and 2940 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum when the fructose component is contained in the blood. In addition, 546 cm ⁻¹ and 2898 cm ⁻¹ are set as the center wave numbers of the peaks appearing in the Raman spectrum when the maltose component is contained in the blood. These set values are input from the input unit 61 and stored as setting data in the second storage area of the storage unit 62. Further, when the blood contains a maltotriose component, 470 cm ⁻¹ and 922 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum.

The component identifying unit 73 recognizes each of the center wave numbers indicated in the setting data read from the second storage area, and searches for a peak within a range of ± 5 cm ⁻¹ with reference to the center wave number. .

Here, when even one peak is detected within a range of ± 5 cm ⁻¹ with respect to each of the above center wave numbers, it means that the blood component corresponding to the peak is contained in the blood. For example, when a peak is detected only in the range of 904 cm ⁻¹ ± 5 cm ⁻¹ , the blood contains only monosaccharide glucose, which is fructose and disaccharide isomers of the glucose. Maltose, a trisaccharide, maltotriose is not included. Further, for example, if the range of 904cm ^-1 ± ^{5cm -1,} a peak in the range of 546cm ^-1 range of ± ^{5 cm -1} and 2898cm ^-1 ± ^{5cm -1} is detected, the blood is monosaccharides It contains glucose and maltose, which is a disaccharide. In this example, fructose, which is an isomer of glucose, and maltotriose, which is a trisaccharide, are not included.

  Thus, the component identification unit 73 can search and identify the sugar components of monosaccharides, disaccharides, and trisaccharides contained in blood. In addition, the component identification unit 73 can search and identify glucose, which is one of important indexes in the discovery and treatment of diseases such as diabetes, and fructose, which is an isomer of the glucose.

  Based on the intensity of the peak detected by the component identification unit 73, the quantification unit 74 obtains the concentration of the blood component corresponding to the peak.

  In the case of the present embodiment, calibration curve data indicating the relationship between the intensity of the Raman spectrum and the concentration corresponding to the intensity is stored in the second storage area of the storage unit 62. Specifically, a glucose calibration curve as illustrated in FIG. 3, a fructose calibration curve as illustrated in FIG. 4, a maltose calibration curve as illustrated in FIG. 5, and a calibration curve as illustrated in FIG. The data of a standard maltotriose calibration curve is stored. 3 to 6, the vertical axis indicates the intensity [intensity] of the spectrum, and the horizontal axis indicates the concentration [mg / dl].

  The quantification unit 74 reads out the calibration curve data of the component corresponding to the peak detected by the component identification unit 73 from the second storage area, and uses, for example, the calibration curve shown in FIGS. The concentration (mg / dl) of the blood component corresponding to the peak is obtained from the intensity of the peak detected by the above. The calibration curve data is input from the input unit 61 and stored in the second storage area of the storage unit 62.

  By the way, the relationship between the intensity of the Raman spectrum and the concentration corresponding to the intensity has a linearity as shown in FIGS. The concentration of the blood component corresponding to the peak may be obtained from the intensity of the peak detected by the component identification unit 73 using a predetermined relational expression indicating the linearity relationship.

  The notification unit 75 notifies the type of blood component that can be detected by the component identification unit 73 and the concentration of the blood component that is detected by the component identification unit 73 and obtained by the quantification unit 74 among the types. Specifically, the type of blood component and the concentration of the blood component obtained by the quantification unit 74 are displayed on the display screen of the display unit 63 in a predetermined display format. Instead of displaying on the display unit 63, or in addition to displaying on the display unit 63, the blood component type and the blood component concentration determined by the quantification unit 74 are output from the speaker. May be.

  The control unit 64 functions as such a spectrum acquisition unit 71, conversion unit 72, component identification unit 73, quantification unit 74, and notification unit 75, and component analysis processing for analyzing components contained in blood is executed.

<First component analysis method>
Next, the 1st component analysis method by the component analyzer 6 in said 1st Embodiment is demonstrated. FIG. 7 is a flowchart showing the first component analysis method. As shown in FIG. 7, the control unit 64 starts component analysis, for example, when a component analysis execution command is given from the input unit 61, and proceeds to the spectrum acquisition step SP1.

  In the spectrum acquisition step SP1, the control unit 64 appropriately adjusts the intensity of light to be emitted from the light source 2 and drives the light source 2, and shows the Raman intensity distribution for each wavelength in the Raman scattered light generated in the sample SPL (blood). After acquiring the spectrum, the process proceeds to the wave number conversion step SP2.

  In the wave number conversion step SP2, the control unit 64 converts the wavelength of the Raman spectrum acquired in the spectrum acquisition step SP1 into a Raman shift amount, and proceeds to the first search step SP3.

Control unit 64, the first search step SP3, searches whether there is a peak in the range of 620 cm ^-1 range of ± ^{5 cm -1} and 2940cm ^-1 ± ^{5cm -1.}

  When no peak is detected in the first search step SP3, the control unit 64 identifies that the sample SPL (blood) does not contain fructose, and the second search step does not pass through the first quantification step SP4. Proceed to SP5. On the other hand, when a peak is detected in the first search step SP3, the control unit 64 identifies that the sample SPL (blood) contains fructose, and proceeds to the first quantification step SP4.

  In the first quantification step SP4, the control unit 64 obtains the concentration of fructose in the blood based on the peak intensity detected in the first search step SP3 and the fructose calibration curve stored in the storage unit 62. The process proceeds to the second search step SP5.

Control unit 64, the second search step SP5, searches whether there is a peak in the range of 470 cm ^-1 range of ± ^{5 cm -1} and 922cm ^-1 ± ^{5cm -1.}

  When the peak is not detected in the second search step SP5, the control unit 64 identifies that the sample SPL (blood) does not contain maltotriose, and does not go through the second quantification step SP6, and the third quantification step SP6. Proceed to search step SP7. On the other hand, when the peak is detected in the second search step SP5, the control unit 64 identifies that the sample SPL (blood) contains maltotriose and proceeds to the second quantification step SP6.

  In the second determination step SP6, the control unit 64 determines the concentration of maltotriose in the blood based on the intensity of the peak detected in the second search step SP5 and the calibration curve for maltotriose stored in the storage unit 62. Is obtained, the process proceeds to the third search step SP7.

Control unit 64, the third search step SP7, searches whether there is a peak in the range of 546cm ^-1 range of ± ^{5 cm -1} and 2898cm ^-1 ± ^{5cm -1.}

  When a peak is not detected in the third search step SP7, the control unit 64 identifies that the sample SPL (blood) does not contain maltose, and does not go through the third quantification step SP8. Proceed to SP9. On the other hand, when a peak is detected in the third search step SP7, the control unit 64 identifies that the sample SPL (blood) contains maltose, and proceeds to the third quantification step SP8.

  In the third determination step SP8, the control unit 64 obtains the maltose concentration in the blood based on the intensity of the peak detected in the third search step SP7 and the maltose calibration curve stored in the storage unit 62. The process proceeds to the fourth search step SP9.

Control unit 64, the fourth search step SP9, searches whether there is a peak in the range of 904cm ^-1 ± ^{5cm -1.}

  When a peak is not detected in the fourth search step SP9, the control unit 64 identifies that the sample SPL (blood) does not contain glucose, and goes to the notification step SP11 without going through the fourth quantification step SP10. move on. On the other hand, when a peak is detected in the fourth search step SP9, the control unit 64 identifies that the sample SPL (blood) contains glucose, and proceeds to the fourth determination step SP10.

  In the fourth determination step SP10, the control unit 64 obtains the glucose concentration in the blood based on the peak intensity detected in the fourth search step SP9 and the glucose calibration curve stored in the storage unit 62. The process proceeds to notification step SP11.

  If the concentrations of glucose, fructose, maltose and maltotriose are not determined in the notification step SP11, the control unit 64 notifies that these sugars are not contained in the blood. On the other hand, when the control unit 64 determines the concentration of any one of glucose, fructose, maltose, and maltotriose, the control unit 64 notifies the saccharide for which the concentration is determined and the concentration. As described above, in the notification step SP11, the control unit 64 notifies the component analysis results from the first search step SP3 to the fourth determination step SP10, and then ends the component analysis.

  In the first analysis method, blood components are searched for in the order of fructose, maltotriose, maltose, and glucose, but an order other than the order may be adopted. In the first analysis method, when a blood component is detected, the detected blood component is quantified before searching for the next blood component. The blood component detected by the search may be quantified.

<Summary>
As described above, the component analyzer 6 according to the present embodiment searches and identifies a plurality of types of sugar components contained in blood. For this reason, it is possible to subdivide and quantify blood sugar, which is one of the important indicators in the discovery and treatment of diseases such as diabetes, and more detailed information than when capturing multiple types of sugar components globally. Can be given. In this way, the component analyzer 6 that can improve the reliability of the analysis result is provided.

  In the case of this embodiment, each sugar component of monosaccharide, disaccharide, and trisaccharide contained in blood is searched and identified. For this reason, it becomes possible to subdivide the kind approximated on the structure of saccharides and to quantify more locally, and to give detailed information accordingly.

Furthermore, in the case of the present embodiment, 904 cm ⁻¹ is set as the center wave number of the peak that appears in the Raman spectrum when the blood contains a glucose component.

When the glucose component is contained in the blood, it has been confirmed by experiments that a peak appears accurately at 904 cm ⁻¹ of the Raman spectrum and has reproducibility. Therefore, the glucose component in the blood can be pinpointed and accurately quantified.

Further, in the present embodiment, 620 cm ⁻¹ and 2940 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum when the fructose component is contained in the blood.

If the fructose component is contained in the blood, that the precise peak at 620 cm ^-1 and 2940 cm ^-1 of the Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, the fructose component in blood can be pinpointed and accurately quantified.

Further, in the case of this embodiment, 546 cm ⁻¹ and 2898 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum when the maltose component is contained in the blood.

If the maltose component is contained in the blood, that the precise peak at 546cm ^-1 and 2898cm ^-1 of Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, the maltose component in the blood can be pinpointed and accurately quantified.

Further, in the case of the present embodiment, 470 cm ⁻¹ and 922 cm ⁻¹ are set as the center wave numbers of peaks that appear in the Raman spectrum when a maltotriose component is contained in blood.

If maltotriose component is contained in the blood, that the precise peak at 470 cm ^-1 and 922cm ^-1 in a Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, the maltotriose component in blood can be pinpointed and accurately quantified.

(1-2) Component Analyzer in Second Embodiment Next, the component analyzer 6 in the second embodiment will be described. Note that the same or equivalent components as those in the first embodiment are denoted by the same reference numerals, and redundant descriptions are omitted as appropriate.

<Configuration of component analyzer>
FIG. 8 is a diagram showing an outline of the configuration of the component analyzer in the second embodiment. As shown in FIG. 8, in the component analysis apparatus 6 of the present embodiment, the functional unit of the control unit 64 that functions when the component analysis program stored in the first storage area of the storage unit 62 is read is different. .

  Specifically, the control unit 64 has the component identification unit 73 that searches for a sugar component in blood in the first embodiment, whereas in this embodiment, the component searches for a component other than the sugar component in blood. An identification unit 83 is included.

In the case of this embodiment, 1002 cm ⁻¹ is set as the center wave number of the peak that appears in the Raman spectrum when the urea component is contained in the blood. Further, 820 cm ⁻¹ and 1682 cm ⁻¹ are set as the center wave numbers of the peaks appearing in the Raman spectrum when ascorbic acid is contained in the blood. Further, as the center wavenumber of the peak appearing in the Raman spectrum if it contains acetaminophen, which is one of the main components of the cold medicine, 854cm ^-1 and 1324cm ^-1 are set. In addition, 804 cm ⁻¹ , 1032 cm ⁻¹ , 1152 cm ^−1, and 1198 cm ⁻¹ are set as the center wave numbers of peaks that appear in the Raman spectrum when acetylsalicylic acid, which is one of the main components of a headache drug, is included. The

The component identifying unit 83 recognizes each of the center wave numbers indicated in the setting data read from the second storage area of the storage unit 62, and whether or not there is a peak within a range of ± 5 cm ⁻¹ with reference to the center wave number. Search for.

Here, when even one peak is detected within a range of ± 5 cm ⁻¹ with respect to each of the above center wave numbers, it is confirmed that blood components other than sugar corresponding to the peak are contained in the blood. means. For example, when a peak is detected only within the range of 1002 cm ⁻¹ ± 5 cm ⁻¹ , urea is contained in the blood, and depending on the concentration, there is a concern about kidney disease. Being detectable is useful.

Further, for example, a range of 1002cm ^-1 ± ^{5cm -1,} if the peak in the range of 820 cm ^-1 ± ^{5 cm -1} and 1682 cm ^-1 ± ^{5 cm -1} is detected, the blood urea and ascorbic acid It is included. Since the concentration of ascorbic acid in the blood may be one of the indices in treatment, it is useful to be able to detect the ascorbic acid. In addition, there is a limit to the blood concentration of ascorbic acid ingested or taken orally, and excessive intake places a burden on the kidney. For this reason, when the urea concentration in the blood is increased, it can be one of the indicators for knowing whether the cause is due to kidney disease or excessive ascorbic acid intake, so that ascorbic acid can be detected. Is useful.

Further, for example, a range of 1002cm ^-1 ± ^{5cm -1,} if the peak in the range of 854cm ^-1 ± ^{5cm -1} and 1324cm ^-1 ± ^{5cm -1} is detected, the blood urea and acetoamino Fen is included. As described above, acetaminophen and acetylsalicylic acid are one of the main components of a drug, and the intake of the drug imposes a burden on the kidney. For this reason, when the urea concentration in the blood is increased, it can be one of the indexes for knowing whether the cause is due to renal disease or drug intake, so that acetaminophen and acetylsalicylic acid can be detected. It will be useful.

  Thus, the component identification unit 83 can search for components other than the sugar component contained in blood.

  Further, the control unit 64 has the quantification unit 74 that quantifies the sugar component in the blood in the first embodiment, whereas the quantification unit 84 that quantifies the component other than the sugar component in the blood in the present embodiment. Have.

  The quantification unit 84 obtains the concentration of the blood component corresponding to the peak based on the peak intensity detected by the component identification unit 83.

  In the case of the present embodiment, as in the first embodiment, the urea calibration curve, ascorbic acid calibration curve, acetaminophen calibration curve, and acetylsalicylic acid calibration curve data are stored in the second storage area of the storage unit 62. Stored. This data is input from the input unit 61.

  The quantification unit 84 reads out the calibration curve data of the component corresponding to the peak detected by the component identification unit 73 from the second storage area, and uses the calibration curve to determine the peak intensity detected by the component identification unit 83. The blood component concentration corresponding to the peak is obtained.

  Note that the calibration curves for urea, ascorbic acid, acetaminophen, and acetylsalicylic acid have generally linearity similar to glucose and the like in the first embodiment. Therefore, the concentration of the blood component corresponding to the peak may be obtained from the intensity of the peak detected by the component identifying unit 83 using a predetermined linear relational expression.

  In addition, the control unit 64 has a notification unit 75 that notifies the analysis result regarding the sugar component in the blood in the first embodiment, whereas the control unit 64 notifies the analysis result regarding the component other than the component in the blood in the present embodiment. The notification unit 85 is provided.

  The notification unit 85 notifies the type of blood component that can be detected by the component identification unit 83 and the concentration of the blood component that is detected by the component identification unit 83 and obtained by the quantification unit 84 among the types. Specifically, the type of blood component and the concentration of the blood component obtained by the quantification unit 84 are displayed on the display screen of the display unit 63 in a predetermined display format. Instead of displaying on the display unit 63, or in addition to displaying on the display unit 63, the blood component type and the blood component concentration determined by the quantification unit 84 are output from the speaker. May be.

  In addition to this, when the concentration unit 84 determines the concentration of any one of acetaminophen and acetylsalicylic acid, which are drug components, by the quantification unit 84, the notification unit 85 determines the concentration and a prescribed value defined in advance. And compare. Here, when the concentration determined by the quantification unit 84 is equal to or higher than a specified value, the notification unit 85 notifies that there is a drug component in the blood.

  Note that the specified value should not be re-measured even if there are drug components in the blood, taking into account the possibility of affecting the measurement of other components other than drug components such as urea and glucose in the blood. It is determined based on the upper limit of the drug concentration to be good. This specified value is input from the input unit 61 and stored as setting data in the second storage area of the storage unit 62. Further, when the concentrations of both acetaminophen and acetylsalicylic acid are obtained by the quantification unit 84, the total concentration thereof may be compared with a specified value, and the higher concentration may be compared with the specified value. .

  The control unit 64 functions as the component identification unit 83, the quantification unit 84, the notification unit 85, the spectrum acquisition unit 71, and the conversion unit 72, and the component analysis process for analyzing the components contained in the blood is executed. .

<Second component analysis method>
Next, the second component analysis method by the component analyzer 6 in the second embodiment will be described. FIG. 9 is a flowchart showing the second component analysis method. As shown in FIG. 9, the control unit 64 starts component analysis, for example, when a component analysis execution command is given from the input unit 61, and sequentially passes through the spectrum acquisition step SP1 and the wave number conversion step SP2 described above. The process proceeds to the first search step SP30.

Control unit 64, the first search step SP30, to search whether there is a peak in the range of 1002cm ^-1 ± ^{5cm -1.}

  When no peak is detected in the first search step SP30, the control unit 64 identifies that the sample SPL (blood) does not contain urea, and does not go through the first quantification step SP40. Proceed to SP50. On the other hand, when a peak is detected in the first search step SP30, the control unit 64 identifies that the sample SPL (blood) contains urea, and proceeds to the first quantification step SP40.

  In the first quantification step SP40, the control unit 64 obtains the urea concentration in the blood based on the peak intensity detected in the first search step SP30 and the urea calibration curve stored in the storage unit 62. The process proceeds to the second search step SP50.

Control unit 64, the second search step SP50, to search whether there is a peak in the range of 820 cm ^-1 ± ^{5 cm -1} and 1682cm ^-1 ± ^{5cm -1.}

  When the peak is not detected in the second search step SP50, the control unit 64 identifies that the sample SPL (blood) does not contain ascorbic acid, and does not go through the second quantification step SP60. Proceed to step SP70. On the other hand, when the peak is detected in the second search step SP50, the control unit 64 identifies that the sample SPL (blood) contains ascorbic acid, and proceeds to the second quantification step SP60.

  In the second determination step SP60, the control unit 64 obtains the concentration of ascorbic acid in the blood based on the intensity of the peak detected in the second search step SP50 and the calibration curve of ascorbic acid stored in the storage unit 62. Then, the process proceeds to the third search step SP70.

Control unit 64, the third search step SP70, to search whether there is a peak in the range of 854cm ^-1 range of ± ^{5 cm -1} and 1324cm ^-1 ± ^{5cm -1.}

  When a peak is not detected in the third search step SP70, the control unit 64 identifies that the sample SPL (blood) does not contain acetaminophen, and without passing through the third quantification step SP80, Proceed to search step SP90. On the other hand, when a peak is detected in the third search step SP70, the control unit 64 identifies that the sample SPL (blood) contains acetaminophen, and proceeds to the third quantification step SP80.

  In the third determination step SP80, the control unit 64 determines the concentration of acetaminophen in the blood based on the intensity of the peak detected in the third search step SP70 and the calibration curve of acetaminophen stored in the storage unit 62. Is obtained, the process proceeds to the fourth search step SP90.

Control unit 64, the fourth search step SP90, the range of 804cm ^-1 ± ^{5cm -1,} a range of 1032cm ^-1 ± ^{5cm -1,} of 1152cm ^-1 ± ^{5cm -1} range and 1198cm ^-1 of ± ^{5 cm -1} Search for a peak within the range.

  When the peak is not detected in the fourth search step SP90, the control unit 64 identifies that the sample SPL (blood) does not contain acetylsalicylic acid, and does not go through the fourth quantification step SP100, but the notification step SP110. Proceed to On the other hand, when a peak is detected in the fourth search step SP90, the control unit 64 identifies that the sample SPL (blood) contains acetylsalicylic acid, and proceeds to the fourth determination step SP100.

  In the fourth determination step SP100, the control unit 64 obtains the concentration of acetylsalicylic acid in the blood based on the intensity of the peak detected in the fourth search step SP90 and the calibration curve of acetylsalicylic acid stored in the storage unit 62. Then, the process proceeds to notification step SP110.

  In the notification step SP110, the control unit 64 obtains the concentration of any one of the drug components acetaminophen and acetylsalicylic acid, and when the concentration is equal to or higher than a predetermined value, That there is a drug component.

  Moreover, the control part 64 notifies that these components are not contained in the blood, when each density | concentration of urea, ascorbic acid, acetaminophen, and acetylsalicylic acid is not calculated | required. On the other hand, when the concentration of any one of urea, ascorbic acid, acetaminophen, and acetylsalicylic acid is obtained, the control unit 64 notifies the type and concentration of the component for which the concentration is obtained. That is, in the notification step SP110, the control unit 64 notifies the component analysis results from the first search step SP30 to the fourth quantification step SP100, and then ends the component analysis.

  In the second analysis method, blood components are searched for in the order of urea, ascorbic acid, acetaminophen, and acetylsalicylic acid, but an order other than the order may be employed. In the second analysis method, when a blood component is detected, the detected blood component is quantified before searching for the next blood component. The blood component detected by the search may be quantified.

<Summary>
As described above, the component analysis apparatus 6 according to the present embodiment searches for and identifies components other than a plurality of types of sugar components contained in blood. Specifically, the urea component is searched and identified. 1002 cm ⁻¹ is set as the center wave number of the peak that appears in the Raman spectrum when this urea component is contained in the blood.

When a urea component is contained in blood, it has been confirmed by experiments that it accurately appears at 1002 cm ⁻¹ of the Raman spectrum and has reproducibility. Therefore, the urea component in the blood can be pinpointed and accurately quantified.

In the case of this embodiment, an acetylsalicylic acid component contained in blood is also searched. ^804cm -1 as the center wavenumber of the peak the acetylsalicylic acid component appears in the Raman spectrum when contained in the ^{blood, 1032cm -1, 1152cm} -1 and 1198cm ^-1 are set.

If acetylsalicylic acid component is contained in the ^blood, 804cm -1 in a Raman ^{spectrum, 1032cm -1,} be accurately found at 1152cm ^-1 and 1198cm ^-1 are also the reproducibility has been confirmed by experiment. Therefore, the acetylsalicylic acid component in the blood can be pinpointed and accurately quantified.

In the case of this embodiment, an acetaminophen component contained in blood is also searched. 854cm ^-1 ± ^{5cm -1} and 1324cm ^-1 ± ^{5cm -1} is set as the center wavenumber of the peak appearing in the Raman spectrum when the acetaminophen component is contained in the blood.

If acetaminophen component is contained in the blood, it appears exactly at 854cm ^-1 ± ^{5cm -1} and 1324cm ^-1 ± ^{5cm -1} in the Raman spectrum there is also the reproducibility has been confirmed by experiment . Therefore, the acetaminophen component in blood can be pinpointed and accurately quantified.

In the case of this embodiment, an ascorbic acid component contained in blood is also searched. When the ascorbic acid component is contained in blood, 820 cm ⁻¹ and 1682 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum.

If ascorbic acid component is contained in the blood, it appears exactly at 820 cm ^-1 and 1682 cm ^-1 in the Raman spectrum there is also the reproducibility has been confirmed by experiments. Therefore, the ascorbic acid component in the blood can be pinpointed and accurately quantified.

(2) Modifications In the above embodiment, monosaccharides, disaccharides, and trisaccharides were searched for as saccharides. However, in addition to monosaccharides, disaccharides, and trisaccharides, or in place of monosaccharides, disaccharides, and trisaccharides, it is possible to search for saccharides that are higher than tetrasaccharides, such as glycogen and amylose.

  Moreover, in the said embodiment, glucose and fructose were searched for as monosaccharide. However, in addition to glucose or fructose, or in place of glucose and fructose, it is possible to search for other monosaccharides other than the glucose and fructose.

  Moreover, in the said embodiment, maltose was searched as a disaccharide. However, in addition to or in place of maltose, it is possible to search for other monosaccharides other than maltose such as sucrose and lactose.

  Moreover, in the said embodiment, maltotriose was searched as a trisaccharide. However, in addition to or instead of maltotriose, it is possible to search for other monosaccharides other than maltotriose.

  Moreover, in the said embodiment, acetylsalicylic acid and acetaminophen were searched for as a chemical | medical agent component. However, in addition to acetylsalicylic acid and acetaminophen, or in place of acetylsalicylic acid and acetaminophen, for example, other drug components other than acetylsalicylic acid and acetaminophen such as dihydrocodeine phosphate, bromvalerylurea, ephedrine hydrochloride, etc. Can be searched. In addition, dihydrocodeine phosphate and the like may cause hallucinations due to excessive intake, and can provide an important index for treatment of diseases.

  In the above embodiment, searching for sugar components of monosaccharides, disaccharides, and trisaccharides contained in blood and searching for components other than sugar components were performed separately. However, searching for sugar components of monosaccharides, disaccharides, and trisaccharides contained in blood and searching for components other than sugar components may be performed as a series of processes. In other words, the function units of the component identification unit, the quantification unit, and the notification unit that execute the first component analysis method and the second component analysis method may be employed.

  When the component identification unit searches for multiple types of sugar components contained in the blood and searches for and identifies urea components contained in the blood, the diabetes is diagnosed and detected at the same time as diabetes prevention, early detection, and treatment. It is possible to provide an important index for prevention, early detection, and treatment of renal diseases that are likely to be complicated. In addition, the dialysis efficiency during artificial dialysis can be managed more closely.

  In addition, when the component identification unit searches for a plurality of types of sugar components contained in blood and searches for and identifies drug components contained in the blood, it may affect the sugar components in the blood. It becomes possible to quantify the drug component it has together with blood sugar. Therefore, when blood sugar is not within the normal range, it is possible to provide an index for determining whether the factor is a drug component. In addition, it is possible to give the possibility of being absorbed from oral food and drink as an index. Furthermore, it can be an indicator of whether or not it is caused by oral administration or when a drug is administered, such as when consciousness disorder occurs, so it is useful in cases of urgency. Will increase.

  In addition, when the component identification unit searches for a plurality of types of sugar components contained in blood and searches for and identifies ascorbic acid components contained in the blood, information on the presence or absence of ascorbic acid deficiency due to diabetes Can be given as. Therefore, it is possible to give a more detailed index that is important for the prevention, early detection, and treatment of diabetes.

  Moreover, in the said embodiment, the blood extract | collected from the person was employ | adopted as the sample SPL irradiated with excitation light. However, the sample SPL irradiated with the excitation light may be an interstitial fluid collected from a person. Further, it may be blood flowing in the human body. When the blood flowing through the human body is used as the sample SPL, for example, the control unit 64 controls the optical system to change the depth of the laser with respect to the human body, and in accordance with the presence or absence of blood components obtained at the depth, Focus on the blood vessels. Further, although human blood is used as the sample SPL, it can be applied to living bodies other than humans such as animals.

  In the above embodiment, the sample SPL is irradiated with excitation light having a single wavelength with respect to the sample SPL. However, as illustrated in FIG. 10, the sample SPL may be irradiated with the first laser beam and the second laser beam having different wavelengths. 10 includes a first light source 21 that emits pump light that is, for example, 1064 nm pulsed laser light, and a second light source 22 that emits Stokes light that is, for example, 1100 nm pulsed laser light. It is done. The pump light emitted from the first light source 21 reaches the dichroic mirror DM through the optical delay device 31. The optical delay device 31 changes the optical path length, for example, and matches the irradiation timing of the pump light with the Stokes light. The Stokes light emitted from the second light source 22 reaches the dichroic mirror DM via the mirror M. In the dichroic mirror DM, the pump light and the Stokes light are superimposed, and the superimposed pump light and Stokes light are collected and applied to the sample SPL. By this irradiation, CARS (Coherent Anti-Stokes Raman Scattering) light having a wavelength different from that of the pump light and different from the wavelength of the Stokes light is generated in the sample SPL. The CARS light generated in the sample SPL passes through the optical filter 42 of the optical system 4 and reaches the spectroscope 5. The optical filter 42 is a filter that cuts stray light other than CARS light. The CARS light reaching the spectroscope 5 is divided for each wavelength by the diffraction grating 51, and Raman spectrum data indicating the intensity distribution for each wavelength of the CARS light is output from the spectroscope 5. Each wavelength in the Raman spectrum is converted by the conversion unit 72 into a wave number that is the number of waves included in the unit length. However, it may not be converted to the Raman shift amount.

  Next, the peak of the acquired Raman spectrum will be described. However, the present invention is not limited to this embodiment. In the examples, an aqueous solution sample containing predetermined components was used instead of blood.

<Peak of glucose component>
The aqueous solution samples having different glucose concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. This acquisition result is shown in FIG. It should be noted that the system conditions for acquiring the Raman spectra of the aqueous solution samples having different glucose concentrations are the same. The glucose concentration of the aqueous solution sample is obtained from a spectrum obtained by isolating a sugar component using liquid chromatography manufactured by Thermo Fisher Scientific and using the charged particle detector.
The vertical axis shown in FIG. 11 indicates the intensity [intensity] of the spectrum, and the horizontal axis indicates the wave number [cm ⁻¹ ]. Further, “glco” shown in the right column of FIG. 11 means glucose, and the numerical value [mg] on the right side of “glco” means the concentration (mg / dl) of glucose in the aqueous solution sample.
As shown in FIG. 11, when the glucose component was contained in the aqueous solution sample, it was found that a peak appeared accurately at 904 cm ⁻¹ of the Raman spectrum and had reproducibility. In FIG. 11, a peak appears at other than 904 cm ⁻¹ , but the peak is a component unrelated to the glucose component.

<Fructose component peak>
The aqueous solution samples having different fructose concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. The acquisition results are shown in FIGS. Note that the system conditions are the same when acquiring the Raman spectra of each of the aqueous solution samples having different fructose concentrations. The fructose concentration of the aqueous solution sample is obtained in the same manner as the glucose concentration.
The vertical axis | shaft shown in FIG.12 and FIG.13 has shown the intensity | strength [intensity] of the spectrum, and the horizontal axis has shown wave number [cm ^<-1 >]. Further, “fulcto” shown in the right column of FIG. 12 and FIG. 13 means fructose, and the numerical value [mg] on the right side of “fulcto” means the concentration of fructose (mg / dl) in the aqueous solution sample. .
As shown in FIGS. 12 and 13, if the fructose component is contained in the aqueous solution sample, exactly the peak at 620 cm ^-1 and 2940 cm ^-1 in the Raman spectrum it was found to be also the reproducibility appearance. Although peak with other than in FIG. 13 2940 cm ^-1 peak other than in FIG. 12 620 cm ^-1 appears has appeared, the peak is irrelevant components fructose component.

<Maltose component peak>
The aqueous solution samples having different maltose concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. The acquisition results are shown in FIGS. Note that the system conditions are the same when acquiring the Raman spectra of each of the aqueous solution samples having different maltose concentrations. The maltose concentration of the aqueous solution sample is obtained in the same manner as the glucose concentration.
The vertical axis | shaft shown in FIG.14 and FIG.15 has shown the intensity | strength [intensity] of the spectrum, and the horizontal axis has shown wave number [cm ^<-1 >]. Further, “malto” shown in the right column of FIG. 14 and FIG. 15 means maltose, and the numerical value [mg] on the right side of “malto” means the concentration (mg / dl) of maltose in the aqueous solution sample. .
As shown in FIGS. 14 and 15, if the maltose component is contained in the aqueous solution sample, exactly the peak at 546cm ^-1 and 2898cm ^-1 of Raman spectrum was found to be also the reproducibility appearance. Although peak with other than in FIG. 15 2898cm ^-1 peak other than in Figure 14 546cm ^-1 appears has appeared, the peak is irrelevant components maltose component.

<Maltotriose component peak>
The aqueous solution samples having different maltotriose concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. The acquisition results are shown in FIGS. In addition, the conditions of the system at the time of acquiring the Raman spectrum of the aqueous solution sample from which maltotriose concentration differs are made the same. Moreover, the maltotriose concentration of the aqueous solution sample is obtained in the same manner as the glucose concentration.
The vertical axis of FIGS. 16 and 17 indicates the intensity [intensity] of the spectrum, and the horizontal axis indicates the wave number [cm ⁻¹ ]. Further, “maltotri” shown in the right column of FIG. 16 and FIG. 17 means maltotriose, and the numerical value [mg] on the right side of “maltotri” represents the concentration (mg / dl) of maltotriose in the aqueous solution sample. I mean.
As shown in FIGS. 16 and 17, if the maltotriose component is contained in the aqueous solution sample, accurately found that peaks appeared also the reproducible 470 cm ^-1 and 922cm ^-1 in a Raman spectrum It was. Although peak with other than in FIG. 17 922cm ^-1 peak other than in FIG. 16 470 cm ^-1 appears has appeared, the peak is irrelevant components and maltotriose component.

<Urea component peak>
The aqueous solution samples having different urea concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. This acquisition result is shown in FIG. Note that the system conditions for acquiring the Raman spectra of the aqueous solution samples having different urea concentrations are the same. The urea concentration of the aqueous solution sample is obtained in the same manner as the glucose concentration.
The vertical axis shown in FIG. 18 indicates the intensity [intensity] of the spectrum, and the horizontal axis indicates the wave number [cm ⁻¹ ]. Further, “urea” shown in the right column of FIG. 18 means urea, and the numerical value [mg] on the right side of “urea” means the concentration (mg / dl) of urea in the aqueous solution sample.
As shown in FIG. 18, when the urea component was contained in the aqueous solution sample, it was found that a peak appeared accurately at 1002 cm ⁻¹ of the Raman spectrum and had reproducibility. In FIG. 18, a peak appears at other than 1002 cm ⁻¹ , but the peak is a component unrelated to the urea component.

<Peak of acetylsalicylic acid component>
The aqueous solution samples having different acetylsalicylic acid concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. A part of this acquisition result is shown in FIGS. In addition, the conditions of the system at the time of acquiring the Raman spectrum of the aqueous solution sample from which acetylsalicylic acid concentration differs are made the same. Moreover, the acetylsalicylic acid concentration of the aqueous solution sample is obtained in the same manner as the glucose concentration.
The vertical axis | shaft shown in FIG.19 and FIG.20 has shown the intensity | strength [intensity] of the spectrum, and the horizontal axis has shown wave number [cm ^<-1 >]. In addition, “acetylsalicylic acid” shown in the right column of FIG. 19 and FIG. 20 means acetylsalicylic acid, and the numerical value [mg] on the right side of “acetylsalicylic acid” means the concentration (mg / dl) of acetylsalicylic acid in the aqueous solution sample. ing.
As shown in FIGS. 19 and 20, if the acetylsalicylic acid component is contained in the aqueous solution ^sample, 804cm -1 in a Raman ^spectrum, 1032Cm -1, precisely peaks at 1152cm ^-1 and 1198cm ^-1 are emerged I found out. Although not shown here, it is known that there is reproducibility. Incidentally, FIG. 20, ^1032cm -1 with peaks other than in Figure 19 804cm ^-1 appears, a peak other than 1152cm ^-1 and 1198cm ^-1 are emerging, the peaks unrelated components and acetylsalicylic acid component It is.

<Peak of acetaminophen component>
The aqueous solution samples having different acetaminophen concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. A part of this acquisition result is shown in FIGS. Note that the system conditions are the same when acquiring the Raman spectra of each of the aqueous solution samples having different acetaminophen concentrations. Moreover, the acetaminophen concentration of the aqueous solution sample is obtained similarly to the glucose concentration.
The vertical axis | shaft shown in FIG.21 and FIG.22 has shown the intensity | strength [intensity] of the spectrum, and the horizontal axis has shown wave number [cm ^<-1 >]. Further, “ruru” shown in the right column of FIG. 21 and FIG. 22 means acetaminophen, and the numerical value [mg] on the right side of “ruru” represents the concentration (mg / dl) of acetaminophen in the aqueous solution sample. I mean.
As shown in FIGS. 21 and 22, if the acetaminophen component is contained in the aqueous solution sample, exactly the peak at 854cm ^-1 and 1324cm ^-1 of Raman spectrum was found to have emerged. Although not shown here, it is known that there is reproducibility. Although peak with other than in FIG. 22 1324cm ^-1 peak other than in Figure 21 854cm ^-1 appears has appeared, the peak is irrelevant components acetaminophen component.

<Peak of ascorbic acid component>
The aqueous solution samples having different ascorbic acid concentrations were irradiated with laser light having a single wavelength of 785 nm, and Raman spectra of the respective aqueous solution samples were obtained. A part of this acquisition result is shown in FIGS. In addition, the conditions of the system at the time of acquiring the Raman spectrum of each aqueous solution sample in which ascorbic acid concentrations differ are the same. The ascorbic acid concentration of the aqueous solution sample is obtained in the same manner as the glucose concentration.
The vertical axis | shaft shown in FIG.23 and FIG.24 has shown the intensity | strength [intensity] of the spectrum, and the horizontal axis has shown wave number [cm ^<-1 >]. “Asco” shown in the right column of FIG. 23 and FIG. 24 means ascorbic acid, and the numerical value [mg] on the right side of “asco” means the concentration (mg / dl) of ascorbic acid in the aqueous solution sample. ing.
As shown in FIGS. 23 and 24, if the ascorbic acid component is contained in the aqueous solution sample, exactly the peak at 820 cm ^-1 and 1682 cm ^-1 in the Raman spectrum was found to have emerged. Although not shown here, it is known that there is reproducibility. Although peaks other than in FIG. 24 1682 cm ^-1 have appeared with a peak other than in FIG. 23 820 cm ^-1 appears, the peak is irrelevant components and ascorbic acid components.

  The present invention may be used in the medical industry.

  DESCRIPTION OF SYMBOLS 1 ... Component analysis system, 2 ... Light source, 3 ... Reflector, 4 ... Optical system, 5 ... Spectroscope, 6 ... Component analyzer, 61 ... Input part, 62 ... storage unit, 63 ... display unit, 64 ... control unit, 71 ... spectrum acquisition unit, 72 ... conversion unit, 73, 83 ... component identification unit, 74, 84 ... -A fixed_quantity | quantitative_assay part, 75,85 ... notification part.

Claims (15)

A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
A component analysis apparatus comprising: a component identification unit that searches and identifies a plurality of types of sugar components contained in blood or interstitial fluid based on the Raman spectrum acquired by the spectrum acquisition unit. The component analysis apparatus according to claim 1, wherein the component identification unit searches for and identifies sugar components of monosaccharides, disaccharides, and trisaccharides. The component identification unit searches for and identifies a plurality of types of sugar components contained in the blood or the interstitial fluid, and searches for and identifies urea components contained in the blood or the interstitial fluid. The component analyzer according to 1. The component identification unit searches for and identifies a plurality of types of sugar components contained in the blood or the interstitial fluid and searches for and identifies drug components contained in the blood or the interstitial fluid. The component analyzer according to 1. The component identification unit searches for and identifies a plurality of types of sugar components contained in the blood or the interstitial fluid and searches for and identifies ascorbic acid components contained in the blood or the interstitial fluid. Item 4. The component analyzer according to Item 1. When a peak corresponding to a component contained in the blood or the interstitial fluid is detected from the Raman spectrum acquired by the spectrum acquisition unit, the apparatus further includes a quantification unit that obtains a concentration based on the intensity of the peak. The component analyzer according to any one of claims 1 to 5, characterized in that: The blood vessel or the interstitial fluid further includes a notification unit for notifying that there is a pharmaceutical component in the blood or interstitial fluid when the concentration of the pharmaceutical component contained in the blood or interstitial fluid is equal to or higher than a specified value. Item 7. The component analyzer according to Item 6. A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
904 cm ⁻¹ is set as a center wave number of a peak appearing in the Raman spectrum when the blood or the interstitial fluid contains a glucose component. A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
620 cm ⁻¹ and 2940 cm ⁻¹ are set as center wave numbers of peaks that appear in the Raman spectrum when a fructose component is contained in the blood or the interstitial fluid. A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
546 cm ⁻¹ and 2898 cm ⁻¹ are set as center wave numbers of peaks appearing in the Raman spectrum when the maltose component is contained in the blood or the interstitial fluid. A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
470 cm ⁻¹ and 922 cm ⁻¹ are set as center wave numbers of peaks appearing in the Raman spectrum when the blood or the interstitial fluid contains a maltotriose component. . A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
1002 cm ⁻¹ is set as a center wave number of a peak appearing in the Raman spectrum when the blood or the interstitial fluid contains a urea component. A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
When the blood or the interstitial fluid contains an acetylsalicylic acid component, 804 cm ⁻¹ , 1032 cm ⁻¹ , 1152 cm ⁻¹ and 1198 cm ⁻¹ are set as the center wave numbers of the peaks appearing in the Raman spectrum. A component analyzer characterized by the following. A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
854 cm ⁻¹ and 1324 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum when the blood or the interstitial fluid contains an acetaminophen component. . A spectrum acquisition unit for acquiring a Raman spectrum indicating an intensity distribution for each wavelength in the Raman scattered light;
Based on the wave number set as the center wave number of the peak appearing in the Raman spectrum according to the component contained in blood or interstitial fluid, and the Raman spectrum acquired by the spectrum acquisition unit, the blood or the interstitial A component identification unit that searches and identifies the components contained in the liquid;
820 cm ⁻¹ and 1682 cm ⁻¹ are set as the center wave numbers of peaks appearing in the Raman spectrum when ascorbic acid is contained in the blood or the interstitial fluid.

Images